The Defense Advanced Research Projects Agency (DARPA) this week announced an award to Agentase, a FLIR Systems company, under the In vivo Nanosensors for Diagnostics (IVN:Dx) program. The contract is valued at $7,958,617.
The overall purpose of the IVN:Dx effort is to develop radically new classes of biocompatible nanosensors that provide continuous, noninvasive, and highly accurate measurement of a variety of conditions and substances within the living tissue of animals, plants, and insects using non-toxic materials with limited immunogenicity.
Such sensors would permit measurements over large concentration ranges of both small (e.g., glucose, lactate, and urea) and large molecules (e.g., proteins, oligonucleotides, infectious agents, and chemical/biological threat agents) in the organism and environment through optical, electronic, thermal or magnetic mechanisms.
The award was announced under Solicitation Number: DARPA-BAA-12-33.
